As a potent inhibitor of DYRK1A with proven safety in clinical trials, CX-4945 will be a valuable tool in DYRK1A-related basic research and in the development of therapeutic drugs for DYRK1A-associated diseases, such as DS and AD. This evidence concerns the gene DYRK1A and Alzheimer disease.